This Article Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frattini, M. Articles by Pierotti, M. A. Search for Related Content PubMed PubMed Citation Articles by Frattini, M. Articles by Pierotti, M. A.

Phosphatase Protein Homologue to Tensin Expression and Phosphatidylinositol-3 Phosphate Kinase Mutations in Colorectal Cancer

Unit of Experimental Molecular Pathology Department of Pathology Istituto Nazionale per lo Studio e la Cura dei Tumori Milan, Italy

Lucio Bertario

Unit of Predictive-Preventive Medicine Istituto Nazionale per lo Studio e la Cura dei Tumori Milan, Italy

Silvia Benvenuti and Carlo Zanon

The Oncogenomics Center Institute for Cancer Research and Treatment University of Torino Medical School Turin, Italy

Alberto Bardelli

The Oncogenomics Center Institute for Cancer Research and Treatment University of Torino Medical School Turin, Italy and Fondazione Italiana per la Ricerca sul Cancro Institute of Molecular Oncology Milan, Italy

Marco A. Pierotti

Department of Experimental Oncology Istituto Nazionale per lo Studio e la Cura dei Tumori and Fondazione Italiana per la Ricerca sul Cancro Institute of Molecular Oncology Milan, Italy

To the Editor:

Phosphatidylinositol-3 phosphate kinase (PI3K) and phosphatase protein homologue to tensin (PTEN) are involved in cell signaling by catalyzing opposite reactions in the balance of phosphatidylinositol-3,4,5,-trisphosphate and are deregulated in many tumors. Recently, Saal et al. (1) reported that these two proteins are altered in a consistent fraction of breast cancers and, more importantly, that PIK3CA mutations and PTEN loss seem mutually exclusive. These results prompted us to verify a possible correlation between PI3K mutations and PTEN protein deregulation also in colorectal cancer, where both of them have been shown to play a relevant role (2, 3).

By screening of 60 colorectal cancers from patients submitted to radical surgery at the National Cancer Institute of Milan, Italy, from 1998 to 2000 (4), we found 12 cases (20%) carrying PIK3CA mutations. These results are in keeping with the literature (2). The same cohort, along with 28 colorectal cancers randomly selected from those lacking PIK3CA mutations, were then analyzed for PTEN protein expression by immunohistochemistry as previously described (1). In our panel, PTEN protein expression was detected mainly at the cytoplasmic level, although occasional nuclear positivity was present. Tumors having reduced or no immunostaining in at least 50% of cells compared with the internal control were considered PTEN negative.

All the cases (12 of 12 = 100%) carrying PIK3CA mutations were PTEN positive (see Supplemental Data). On the contrary, among tumors without PIK3CA mutation, only 14 cases (14 of 28 = 50%) showed PTEN immunodecoration. This difference is statistically significant (P = 0.001728, two-sided Fisher's exact test). Interestingly, seven cases were completely PTEN immunonegative (see Supplemental Data). We also observed a trend toward PTEN protein reduction in mucinous colorectal cancers, compared with well-differentiated tumors. No association between PIK3CA and PTEN deregulation and those occurring in the markers mainly involved in colorectal carcinogenesis (APC, K-Ras, DCC, and TP53; ref. 4) was observed.

Our results point out that PTEN and PIK3CA are altered in a consistent number of colorectal cancers and that PIK3CA mutations and PTEN protein deregulation are mutually exclusive. Moreover, because other members of the PI3K pathway (PDPK1, AKT2, and PAK4) have been recently found to be altered in human tumors carrying PIK3CA wild-type gene (5), we could assume that colorectal cancers carrying normal expression of PTEN protein and PIK3CA wild-type gene might present a mutation in one of these genes. Our data, therefore, support the notion that the PTEN/PI3K/AKT pathway could represent an attractive target for pharmacologic interventions in this type of tumors.

Footnotes

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

References

1. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554–9.[Abstract/Free Full Text]
2. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.[Free Full Text]
3. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its function and alterations in human cancer. Apoptosis 2004;9:667–76.[CrossRef][Medline]
4. Frattini M, Balestra D, Suardi S, et al. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 2004;10:4015–21.[CrossRef][Medline]
5. Parsons DW, Wang TL, Bardelli A, et al. Mutational analysis of the serine/threonine kinome in colorectal cancers identifies alterations in PI3K pathway genes. Nature 2005;436:792.[CrossRef][Medline]

This article has been cited by other articles:

				S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer J Natl Cancer Inst, October 7, 2009; 101(19): 1308 - 1324. [Abstract] [Full Text] [PDF]

				P. Laurent-Puig, A. Lievre, and H. Blons Mutations and Response to Epidermal Growth Factor Receptor Inhibitors Clin. Cancer Res., February 15, 2009; 15(4): 1133 - 1139. [Abstract] [Full Text] [PDF]

				M. Jhawer, S. Goel, A. J. Wilson, C. Montagna, Y.-H. Ling, D.-S. Byun, S. Nasser, D. Arango, J. Shin, L. Klampfer, et al. PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab Cancer Res., March 15, 2008; 68(6): 1953 - 1961. [Abstract] [Full Text] [PDF]

This Article Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frattini, M. Articles by Pierotti, M. A. Search for Related Content PubMed PubMed Citation Articles by Frattini, M. Articles by Pierotti, M. A.